ArticleEpigenetics2016
Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.
Article in Epigenetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 50 citations in OpenAlex.
- DNA methylation marker to estimate the breast cancer cell fraction in DNA samples.Medical oncology (Northwood, London, England) · 2018Trial
- The Years 2015-2025 as a Prospective Decade for the Identification of Specific Methylation Biomarkers of Prostate Cancer.Biomolecules · 2025Review
- Multiple highly methylated CpG sites as potential epigenetic markers for the diagnosis of prostate cancer.Clinical epigenetics · 2025Article
- Detection of differentially methylated CpGs between tumour and adjacent benign cells in diagnostic prostate cancer samples.Scientific reports · 2024Article
- MicroRNAs Associated with IgLON Cell Adhesion Molecule Expression.Current issues in molecular biology · 2024Review
- The NEDD4/FLRT2 axis regulates NSCLC cell stemness.Frontiers in pharmacology · 2024Article
- Establishing a Prediction Model for the Efficacy of Platinum-Based Chemotherapy in NSCLC Based on a Two Cohorts GWAS Study.Journal of clinical medicine · 2023Article
- Fibronectin leucine-rich transmembrane protein 2 drives monocyte differentiation into macrophagesFrontiers in immunology · 2023Article
- Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.Frontiers in immunology · 2022Article
- Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.Cancer science · 2021Article
- Identification of DNA methylation biomarkers for risk of liver metastasis in early-stage colorectal cancer.Clinical epigenetics · 2021Article
- Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer.Breast cancer (Tokyo, Japan) · 2021Article
- An aging and p53 related marker:Aging · 2021Article
- Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.Cancer gene therapy · 2021Review
- Gene Size Matters: An Analysis of Gene Length in the Human Genome.Frontiers in genetics · 2021Article
- Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.Frontiers in genetics · 2021Article
- FLRT2 functions as Tumor Suppressor gene inactivated by promoter methylation in Colorectal Cancer.Journal of Cancer · 2020Article
- PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer.Medeniyet medical journal · 2020Article
- Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
To develop new methods to distinguish indolent from aggressive prostate cancers (PCa), we utilized comprehensive high-throughput array-based relative methylation (CHARM) assay to identify differentially methylated regions (DMRs) throughout the genome, including both CpG island (CGI) and non-CGI regions in PCa patients based on Gleason grade. Initially, 26 samples, including 8 each of low [Gleason score (GS) 6] and high (GS ≥7) grade PCa samples and 10 matched normal prostate tissues, were analyzed as a discovery cohort. We identified 3,567 DMRs between normal and cancer tissues, and 913 DMRs distinguishing low from high-grade cancers. Most of these DMRs were located at CGI shores. The top 5 candidate DMRs from the low vs. high Gleason comparison, including OPCML, ELAVL2, EXT1, IRX5, and FLRT2, were validated by pyrosequencing using the discovery cohort. OPCML and FLRT2 were further validated in an independent cohort consisting of 20 low-Gleason and 33 high-Gleason tissues. We then compared patients with biochemical recurrence (n=70) vs. those without (n=86) in a third cohort, and they showed no difference in methylation at these DMR loci. When GS 3+4 cases and GS 4+3 cases were compared, OPCML-DMR methylation showed a trend of lower methylation in the recurrence group (n=30) than in the no-recurrence (n=52) group. We conclude that whole-genome methylation profiling with CHARM revealed distinct patterns of differential DNA methylation between normal prostate and PCa tissues, as well as between different risk groups of PCa as defined by Gleason scores. A panel of selected DMRs may serve as novel surrogate biomarkers for Gleason score in PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.